CD274 and neoplasm: Due to tumor overexpression of PD-L1, the incorporation of PD-1 inhibitors, such as pembrolizumab and nivolumab, into the therapeutic arsenal for HL represents something which has already been established in an R/R setting and under development in first line [84].